← Back to Search

Anti-metabolites

Vidaza and Valproic Acid for Acute Myeloid Leukemia

Phase 2
Waitlist Available
Led By Patrick Stiff, MD
Research Sponsored by Patrick Stiff
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

This trial is testing a combination of azacitidine and valproic acid as maintenance therapy for high-risk MDS/AML patients post allogeneic stem cell transplantation. The goal is to improve outcomes and extend 1 year survival rates.

Eligible Conditions
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Survival
Secondary study objectives
Disease Relapse

Trial Design

1Treatment groups
Experimental Treatment
Group I: Vidaza and Valproic AcidExperimental Treatment1 Intervention
Vidaza and Valproic Acid

Find a Location

Who is running the clinical trial?

Patrick StiffLead Sponsor
Patrick Stiff, MDPrincipal Investigator - Faculty
Loyola University Medical Center, St. Joseph Regional Medical Center
Loyola University Of Chicago Stritch School Of Medicine (Medical School)
Cleveland Clinic Fndn (Residency)
8 Previous Clinical Trials
401 Total Patients Enrolled
~4 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top